Your Yourlocation: Home > Tiotropium bromide(136310-93-5) is a core drug used to treat COPD and asthma

On July 31, 2014, Boehringer Ingelheim's COPD drug, Striverdi (olodaterol), was approved by the FDA, announcing the addition of a slightly overcrowded COPD drug market. Of course, Boehringer Ingelheim is not a novice to develop drugs for respiratory diseases, its key core products for the treatment of COPD and asthma Spiriva (tiotropium bromide(136310-93-5)), 2013 sales of about 4.8 billion US dollars. Striverdi's approval for Boehringer Ingelheim enriched the product layout in the COPD market.

In addition to respiratory drugs developed for large groups of patients, Boehringer Ingelheim also developed a specific treatment of pulmonary fibrosis drug nintedanib, and in June 2011 by the FDA orphan drug eligibility, in June 2013 to enter the FDA fast-track, Its application for new drug listing has been accepted by the FDA on July 2 and granted priority review of eligibility, EMA is also on June 5 received a listing review nintedanib and granted to accelerate the eligibility of approval, Boehringer respiratory products business can continue Strong end of the year can be announced.

In addition, Boehringer is also developing olodaterol + tiotropium bromide(136310-93-5) (LABA + LAMA) compound drugs, phase III study results show that fixed-dose combination of tiotropium bromide(136310-93-5) and olodaterol COPD patients can improve lung function, and the effect is better than Placebo and the two components used alone, if the compound to obtain FDA approval, the US market LABA + LAMA combination will no longer be the only GSK Anoro sing the one-man show, Boehringer in GSK competition in the fighting will Significant upgrade.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved